Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

endpoints.news image

News from endpoints.news

Your destination for news from endpoints.news. See how endpoints.news’s media bias impacts the breaking news stories of today.

We’ve discovered 115 headlines written by endpoints.news during the past 3 months.

endpoints.news’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

endpoints.news’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about endpoints.news

Where is endpoints.news located?endpoints.news's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top endpoints.news News

Kennedy names 8 vaccine committee replacements, including COVID shot critic

US Politics · United States

Kennedy names 8 vaccine committee replacements, including COVID shot critic

60% Center coverage: 234 sources

U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week.See the Story

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

Europe · Germany

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

47% Center coverage: 28 sources

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.See the Story

World-first blood cancer therapy to be given on NHS

World-first blood cancer therapy to be given on NHS

52% Center coverage: 17 sources

Blindspots

23andMe to Reopen Bankruptcy Court Auction After Anne Wojcicki Group's ...

Anne Wojcicki’s Nonprofit Wins Bid to Acquire Genetic Testing Company 23andMe

72% Center coverage: 14 sources

By Auzinea Bacon, CNN (CNN) — A nonprofit led by Anne Wojcicki, the co-founder and former chief executive of 23andMe, won a bid to acquire the genetic testing company following its bankruptcy filing in March. Wojcicki’s California-based nonprofit, TTAM Research Institute, will purchase 23andMe for $305 million, according to a news release on Friday. It’s the final twist in the bidding war between TTAM and Regeneron Pharmaceuticals, which announc…23andMe · United States See the Story

Kennedy's new vaccine adviser was expert witness against Merck vaccine

Coverage: 10 sources

Robert F. Kennedy Jr. · United States See the Story

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

KalVista Pharmaceuticals said Friday that the FDA pushed back its decision on whether to approve its on-demand oral drug for hereditary angioedema, citing “heavy workload and limited resources” at the agency. KalVista had expected the ...United States · United States Read Article

Another round of consolidation is coming, FDA commissioner tells staff

FDA Commissioner Martin Makary sent an email to staff this week announcing plans to further consolidate the agency’s operations outside of medical product reviews and inspections. Human resources, acquisitions, travel, budget, FOIA/disclosures, facilities, communications and ...Silver Spring · Silver Spring Read Article

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

A groundbreaking new therapy that can almost entirely prevent HIV is days away from an FDA decision — but a mix of recent federal politics and historically slow launches may get in its way. At stake ...HIV · United States Read Article

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

Plus, news about Enliven Therapeutics, Merck's Keytruda and Celldex: FDA places hold on Rein study: The agency has “non-clinical requests” for Rein Therapeutics’ Phase 2 trial in idiopathic pulmonary fibrosis, per a Thursday ...Merck Read Article

Bristol Myers Squibb Names Shibutani as EVP, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post. Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experi…CEOs · New Jersey See the Story

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

100% Center coverage: 4 sources

AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder. The post AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pa…Pharma See the Story

Breaking News Topics Related to endpoints.news